In the MONALEESA-2 study, ribociclib demonstrated significant PFS and OS benefits when combined with an aromatase inhibitor (AI) to treat postmenopausal patients with HR-positive, HER2-negative advanced breast cancer [7]. Here, ERBB2 is linked to breast carcinoma.